Drug Trial Radar · NCT07489482
A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 2, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.
Conditions
- Diabetes Mellitus
Interventions
SHR-3167 InjectionDrug
SHR-3167 injection, different specifications.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximum plasma concentration (Cmax)Time frame: Day 1 - Day 71.
- The area under the blood drug concentration-time curve corresponding from time 0 to the last quantifiable concentration time (AUC0-t)Time frame: Day 1 - Day 71.
- The area under the blood drug concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Day 1 - Day 71.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital, Central South University
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.